BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Anima Biotech

Anima Biotech logo

Founded
2014
Patents
7
Publications
3

Technologies

AI Companies (Drug Discovery) RNA-focused Startups

Anima Biotech is advancing mRNA Lightning, a novel platform for the discovery of selective small molecule mRNA drugs and their mechanisms of action. Our differentiated approach combines high scale automated phenotypic screening in live biology with AI mRNA image analysis.

The high scale automation and integrated technologies in our platform enabled us to develop a broad pipeline across 18 different discovery programs in various therapeutic areas. With our tremendous expertise in mRNA biology, we were able to advance them at unprecedented speed and success rate.

Our wholly owned pipeline programs are in Fibrosis (tissue selective Collagen I translation inhibitors across several fibrotic diseases), Oncology (c-Myc and K-Ras translation inhibitors with multiple, tumor specific mechanisms of action), Infectious diseases (RSV viral proteins translation inhibitors), and Neuroscience (Alzheimer’s disease – Tau translation inhibitors and Pain - Nav1.7 translation inhibitors) with additional programs in Repeat Associated Diseases.

In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our large scale collaborations with Lilly and Takeda Pharmaceuticals.


Posts Mentioning This Company

What Makes Israel's Life Sciences Ecosystem Successful?

  
Israel's biotech sector has been considered secondary to its thriving Medtech field for decades. Still, the turn of millennia brought a significant shift to the biotech landscape in the country. Part of the growth originates from Israel’s focus on building a solid education with roughly 6% of GDP being spent on …

9 Companies Using Artificial Intelligence to Fight Infectious Diseases

  
Development of a novel drug is a tedious process that requires immense investments of resources and time - on average, it takes at least ten years and $ 2.6 B for a new medicine to complete the journey from initial discovery to the marketplace. And then patents give pharmaceutical companies …
SHARE